Myriad Genetics, Inc.
MYGNHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframePart of the healthcare sector, Myriad Genetics, Inc. (MYGN) is listed under Diagnostics & Research. The $583.7M market capitalization puts MYGN squarely in small-cap range for its industry. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Market Cap
$583.7M
Beta
1.64
P/E (TTM)
—
P/E (Fwd)
40.90
EPS (TTM)
$-4.30
EPS (Fwd)
$0.15
ROE
-23.5%
ROA
-7.6%
Cash
$150.7M
Total Debt
$0
Free CF
-$46.1M
52W Change
38.3%
Annual Financials
Cash vs Debt
Myriad Genetics, Inc. reports $150.7M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$46.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -23.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $678.4M (2022) to $824.5M (2025), reflecting a 22% increase over the period.
Myriad Genetics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing MYGN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.